Alirocumab for the treatment of hypercholesterolemia

Medicine & Life Sciences

• alirocumab 100%
• Hypercholesterolemia 59%
• Proprotein Convertase 9 34%
• LDL Cholesterol 32%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 23%
• Hyperlipoproteinemia Type II 14%
• Maximum Tolerated Dose 13%
• Safety 13%
• Subcutaneous Injections 12%
• Expert Testimony 12%
• Therapeutics 9%
• Pharmacokinetics 8%
• Monoclonal Antibodies 8%
• Cardiovascular Diseases 8%
• Lipids 7%
• Clinical Trials 7%
• Costs and Cost Analysis 7%
• Pharmaceutical Preparations 4%

Chemical Compounds

• Low-Density Lipoprotein Cholesterol 94%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 57%
• Safety 33%
• Antilipemic Agent 30%
• Reduction 17%
• Dose 15%
• Pharmacokinetics 14%